Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Adcetris plus Chemo Gets EU Panel OK for Front-Line Use: Takeda
April 2, 2020
- Chugai Maps Out Digital Vision for 2030 Aiming at Value Chain Optimization, Novel Drug Discovery
April 2, 2020
- Takeda Introduces Claw-Back Policy for Executives Liable for Business Loss, Misconducts
April 2, 2020
- Post-Promotion Guidelines - 2: Takeda Evaluating “Non-Sales” Factors through Quality Conversations with Bosses
April 1, 2020
- Myovant Licenses European Rights for Relugolix Combo to Gedeon Richter
April 1, 2020
- SanBio Ties Up with China’s Ocumension for Stem Cell Therapies for Eyes
April 1, 2020
- Shionogi Files Xofluza for Post-Exposure Prophylaxis in Taiwan
April 1, 2020
- Fujifilm Launches Avigan Trial with Completion Eyed in June; Sanofi Too to Test Kevzara in Japan
April 1, 2020
- Astellas Suspends Launch of New Clinical Studies in Virus-Hit Countries
April 1, 2020
- Eiken’s Novel Coronavirus Detection Reagent Kit Approved, with Launch Planned in Mid-April
April 1, 2020
- Shionogi Hooks Up with China’s Biggest Insurance Group, Eyes RWD-Based Drug Development
March 31, 2020
- Ono Expands I/O Collaboration with Swiss Firm Numab
March 31, 2020
- Fujifilm Wants to Launch Avigan Trial in Japan by End of This Week, Abe Talks to WHO Chief
March 31, 2020
- Healios to Boost Its Stake in US Biotech Athersys
March 31, 2020
- Daiichi Sankyo Files Yescarta, Second CAR-T Therapy in Japan
March 30, 2020
- Daiichi Sankyo Shares Anti-Coronavirus Measures, Development Plan
March 30, 2020
- Daiichi Sankyo, Kitasato Pharma End Flu Vaccine Collaboration
March 30, 2020
- India Lockdown Derails Japan-Bound APIs, Intermediate Exports
March 30, 2020
- US FDA Accepts Xofluza’s Granule Version, Pediatric Use for Review: Shionogi
March 30, 2020
- Kissei Licenses CG Oncology's Oncolytic Viral Therapy in Asia Excluding China
March 30, 2020
ページ
The number of newly listed generic drugs in Japan has fallen sharply over the past decade, reflecting structural changes in…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…